Mode
Text Size
Log in / Sign up
N/A N=263 Randomized Triple-blind Prevention

Does Capnography Prevent Hypoxemia During Endoscopic Retrograde Cholangiopancreatography and Endoscopic Ultrasound?

Hypoxemia

Enrolled (actual)
263
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Number of Participants Experiencing Hypoxemia During Endoscopy — 57; 85 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Capnography (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The Cleveland Clinic
Primary completion
Sep 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Experiencing Hypoxemia During Endoscopy
57; 85
SECONDARY
Proportion of Participants Requiring Supplemental Oxygen
65; 82
SECONDARY
Proportion of Participants Experiencing Severe Hypoxemia
19; 38
SECONDARY
Proportion of Participants Experiencing Apnea
51; 77

Summary

Subjects undergoing elective ERCP and EUS will receive standard monitoring and sedation. In addition, capnography which measures carbon dioxide levels and can graphically assess respiratory activity will be used. Subjects will be randomized to either a capnography blinded or titration arm. In the capnography titration arm, the endoscopy team would be made aware of capnographic abnormalities as they arise throughout the procedure. In the capnography blinded arm, this information will not be available to the endoscopy team and represents standard of care. It is our hypothesis that using capnography can prevent low oxygen levels known as hypoxemia, during these procedures.

Eligibility Criteria

Inclusion Criteria

  • Adults age 18 or greater
  • Subjects undergoing elective ERCP and EUS
  • ASA class 1-3
  • Inpatient and outpatient
  • Able to give informed consent

Exclusion Criteria

  • ASA Class 4 and 5
  • Emergent procedures
  • Procedures requiring MAC sedation
  • Subjects unable to give informed consent
  • Subjects on oxygen before procedure
  • Subjects on CPAP/BiPAP
  • Allergies to fentanyl/demerol/midazolam
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00675415). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search